Genmab faced a looming revenue cliff as Darzalex patent expirations approach, while the company leans on three oncology assets for next readouts. A report highlighted that Epkinly’s late-stage lymphoma data and results for rinatabart sesutecan (Rina-S) in ovarian cancer, alongside an upcoming Phase 3 for Rina-S and potential pivotal timing for petosemtamab, are framed as make-or-break catalysts. The coverage emphasized the market pressure from Darzalex royalty concentration and the scale of potential erosion if new assets fail to offset. Analysts cited a view that Genmab has sufficient pipeline “horsepower,” but focused attention on the binary risk of petosemtamab’s trajectory relative to other programs. For biotech watchers, the takeaway is not only the company-specific outlook, but how closely investor narratives are tied to readout timing across antibody and ADC modalities. Upcoming efficacy and durability updates will likely determine whether Genmab’s diversified pipeline can stabilize long-term growth after flagship patent losses.